- PR Newswire•8 months agoFDA-Cleared DigniCap® Scalp Cooling System Is Now Available For Women With Breast Cancer At 10 U.S. Cancer Treatment Centers
DALLAS, March 29, 2016 /PRNewswire/ -- Dignitana Inc., a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared by the FDA in December to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at ten cancer treatment centers across the United States. Scalp cooling is administered alongside chemotherapy in medical infusion centers. The DigniCap® system is the first and only scalp cooling device to complete rigorous FDA clinical trials in the U.S., where seven out of 10 patients with early-stage breast cancer kept at least 50% of their hair.
- Associated Press•last year
WASHINGTON (AP) — Hair loss is one of the most despised side effects of chemotherapy, and now breast cancer patients are getting a new way to try to save their locks.
We're sorry this is all we were able to find about this topic.
DIGN.ST : Summary for Dignitana AB - Yahoo Finance
Dignitana AB (DIGN.ST)
Stockholm - Stockholm Delayed Price. Currency in SEK
Add to watchlist
|Day's Range||18.00 - 19.00|
|52 Week Range||14.60 - 23.58|
|PE Ratio (TTM)||-13.01|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|